Viva Biotech Holdings

1873

KYG9390W1015

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:39:05 07/06/2024 pm IST			5-day change	1st Jan Change
0.64 ^HKD	+3.23%		+3.23%	-39.05%

28/03	Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/01	Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director	CI

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

March 19, 2021 at 05:51 pm IST

Viva Biotech Holdings provided earnings guidance for the year ended December 31, 2020. For the year, the company expected net loss no higher than RMB 400 million, as compared to the net profit of approximately RMB 266 million for the year ended December 31, 2019.

Latest news about Viva Biotech Holdings

Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director	18/01	CI
VIVA Biotech Redeems $280 Million Convertible Bonds Ahead of 2025 Maturity	03/01	MT
VIVA Biotech Sells 2.3% Stake in Viva Biotech (Shanghai)	27/12	MT
VIVA Biotech Disposes of Minority Stake in Subsidiary for $15 Million	18/12	MT
Viva Biotech Holdings Announces Executive Changes	01/12	CI
Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer	01/12	CI
Viva Biotech Buys Back $143.4 Million Convertible Bonds	28/11	MT
Viva Biotech Buys Back $56.3 Million of Convertible Bonds Due 2025	21/11	MT
Viva Biotech Disposes 24% Stake in Subsidiary	20/11	MT
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) completed the acquisition of an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings.	20/11	CI
Viva Biotech Completes Post-Issue Regulatory Filing for Convertible Bonds	26/23/26	MT
Viva Biotech Buys Back $43 Million of 1% Convertible Bonds	13/23/13	MT
Viva Biotech Holdings commences an Equity Buyback Plan for 193,503,680 shares, representing 10% of its issued share capital, under the authorization approved on June 30, 2023.	28/23/28	CI
Viva Biotech Logs 64% Jump in H1 Profit	30/23/30	MT
Viva Biotech Holdings Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Viva Biotech to Swing to H1 Profit	18/23/18	MT
Viva Biotech Holdings to Sell 24% of Subsidiary for 1.06 Billion Yuan	09/23/09	MT
Viva Biotech Raises HK$470 Million from Convertible Bonds	10/23/10	MT
Viva Biotech Holdings announced that it has received HKD 470 million in funding	07/23/07	CI
Viva Biotech to Potentially Raise HK$11.7 Million through Share Issue to Individual Affiliates	12/23/12	MT
Viva Biotech Issues HK$470 Million in Convertible Bonds; Shares Fall 12%	12/23/12	MT
Temasek-backed firms buy stake in VIVA Biotech unit ahead of listing	12/23/12	RE
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) entered into an agreement to acquire an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings for CNY 514.6 million.	11/23/11	CI
Viva Biotech Holdings announced that it expects to receive HKD 470 million in funding	10/23/10	CI

Chart Viva Biotech Holdings

Duration

Period

More charts

Company Profile

VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Companyâs core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.

Sector

Pharmaceuticals

Calendar

26/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VIVA BIOTECH HOLDINGS	-39.05%	18Cr
ELI LILLY AND COMPANY	+45.82%	77TCr
NOVO NORDISK A/S	+40.95%	63TCr
JOHNSON & JOHNSON	-6.16%	35TCr
MERCK & CO., INC.	+19.86%	33TCr
ABBVIE INC.	+9.32%	30TCr
ASTRAZENECA PLC	+18.45%	25TCr
ROCHE HOLDING AG	-0.78%	22TCr
NOVARTIS AG	+11.88%	22TCr
AMGEN INC.	+5.90%	16TCr

Other Pharmaceuticals